The Flemish government has awarded an investment of 15 million euros to RegMed XB, the Flemish-Dutch collaborative initiative for regenerative medicine, of which SBMC is a part.
This funding marks a significant impulse for the development of new therapies, with specific focus on osteoarthritis and eye diseases. These therapies are being developed by a consortium of leading knowledge institutions and companies from both Flanders and the Netherlands. The investment will also be used to strengthen the collaboration and unite efforts to improve healthcare.
“Thanks to this investment, we are able to develop two promising research programs with a lot of Flemish partners, and thus develop new products for regenerative medicine” says Bart Geers, chairman of RegMed XB Flanders VZW. “It also allows us to establish an integrated Flemish-Dutch management structure for scaling up those programs on both sides of the border.”
Bernard Mulder, CEO of RegMed XB Netherlands adds: “Over the past few years, RegMed XB has paved the way for new projects, thematically focused on regenerative medicine with partners from Flanders and the Netherlands. With this new Flemish boost, we can shift up a gear and take further steps to move the first products towards the patients.”
“RegMed XB is a fine example of an intensive scientific collaboration between Flanders and the Netherlands, which sets a precedent for similar collaborations we want to build in the future”, according to Jo Brouns, Flemish Minister of Economy, Science and Innovation. “We look forward to positioning Flanders, together with the Netherlands, as a hub for regenerative medicine. In doing so, we strive with innovations in healthcare to make life better for people, as sick organs are healed faster and more effectively.”